Quote:I expect some validation news like a license deal to begin it as it will fix much of the financial woes, positive cancer results, Dr. Sacha PrEP/cure news, BLA acceptance, etc could all make for some deserved moves towards fair valuation.
I think you are exactly right. And look at Anson’s two comments about drug approval and financing. With the BLA submission we get much closer, some will wake up at that point, then financing woes fixed, both issues are addressed. Right now it sounds promising that there might be a partnership or licensing of some kind that both sides can agree on for leronlimab.
(Another comment to Anson, who found this board, maybe from my post on yahoo with the twitter link, that was intentional, so others can find their way here, including you. And the issue with SS, is when they are in the stock, they have no concerns, stocks has a value of dollars, when they are not in the stock, they stock is worthless, going bankrupt. Just look last year when they were not in the stock, right after the did a pump and dump in july, with the 2018 10k in August, they said $100M would be needed for this year, I said little over 50M, it came in at $56M. They are overly pessimistic, when they don't own stock. You haven’t been around long enough to see them switch back and forth from one opinion to the other, depending on their stock position. Also Ludwig, seaofsand, are the same group, sometimes person, they have many accounts, talking among themselves. Their unfortunate shenanigans has hurt the stock, because when new people pop up with similar concerns, a lot of the time it has been them, just with a new account. But the financing picture, being ugly now, yes, I believe we get clarity soon, after the BLA submission, with finally non-dilutive financing. Note: The company could just R/S 20:1, knocking the O/S to 20M, price $8, sell 5M shares for $40M, with warrants most likely, to clear all that up. But that would have the current shareholders taking a big cut. They believe that can do it without that path, the BOD being the major shareholders, that is always part of their decision. They believe the best path is that they should raise just enough money, limb along financially, until a infection point, which is why the financing looks ugly. And my point they could fix it now if they wanted, but the feel at the cost to current shareholders, it is better to wait. With leonlimab near BLA submission, they will be able to raise money, if needed. I am not concerned there.)
